TY - JOUR
T1 - New antithrombotics in the treatment of thromboembolic disease
AU - Levi, Marcel
PY - 2005
Y1 - 2005
N2 - New insights into the in vivo function of the coagulation system have resulted in the development of new antithrombotic agents with a more specific point of impact and more reliable pharmacological properties. Inhibition of coagulation can be achieved by specific thrombin inhibitors (e.g. melagatran), agents specifically targeted at factor Xa (e.g. pentasaccharides), and by tissue factor/factor VIIa blockers (e.g. recombinant NAPc2). In some situations, these agents are more effective and safer than the antithrombotics currently used. However, the major difference may be that the newer generation of antithrombotics does not require repeated laboratory control and dose adjustment to obtain a stable level of anticoagulation; therefore, they are more suitable for application in clinical practice. In this overview, we will briefly discuss the various new compounds that have recently become available or that will be introduced into clinical medicine in the near future and their relative efficacy and safety in comparison to currently used antithrombotic agents
AB - New insights into the in vivo function of the coagulation system have resulted in the development of new antithrombotic agents with a more specific point of impact and more reliable pharmacological properties. Inhibition of coagulation can be achieved by specific thrombin inhibitors (e.g. melagatran), agents specifically targeted at factor Xa (e.g. pentasaccharides), and by tissue factor/factor VIIa blockers (e.g. recombinant NAPc2). In some situations, these agents are more effective and safer than the antithrombotics currently used. However, the major difference may be that the newer generation of antithrombotics does not require repeated laboratory control and dose adjustment to obtain a stable level of anticoagulation; therefore, they are more suitable for application in clinical practice. In this overview, we will briefly discuss the various new compounds that have recently become available or that will be introduced into clinical medicine in the near future and their relative efficacy and safety in comparison to currently used antithrombotic agents
U2 - https://doi.org/10.1016/j.ejim.2004.11.009
DO - https://doi.org/10.1016/j.ejim.2004.11.009
M3 - Article
C2 - 16084349
SN - 0953-6205
VL - 16
SP - 230
EP - 237
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
IS - 4
ER -